Antibodies Program News Today

EQS-News: Evotec SE / Key word: Miscellaneous Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies...

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS MABS TARGETING ORTHOPOXVIRUSESPROJECT INCLUDES EXISTING ANTIBODY DEVELOPMENT, ANTIBODY DISCOVERY, AND AI-DRIVEN DE

Just - Evotec Biologics Awarded Second Contract from U.S. Department ...

By illuminating landmarks across the country, a campaign brought new visibility to a disease and a foundation.

22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 MPOSITIVE MOMENTUM AND OUTLOOK FOR 2023DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRYHAMBURG

EQS-News: Evotec SE / Key word(s): Annual ResultsEvotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year 28.03.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. 22% INCREASE IN GROUP REVENUES; EBITDA EXCLUD...

EQS-News: EVOTEC SE / Key word(s): Annual Results Evotec SE preliminary fiscal year 2022 results: Ahead of the curve very strong p...

EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec presents paradigm shift in biologics at Capital Markets Day 02.11.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.  TOGETHER FOR MEDICINES THAT MATTER: A PARADIGM SHIFT TO UNLOCK NEW MARKETS AND OPPORTUNITIES FOR G...

HAMBURG (dpa-AFX) - German drug maker Evotec SE (EVTCY.PK, EVOTF.PK) announced Tuesday that its Seattle-based unit, Just - Evotec Biologics, Inc., has received a contract from the U.S. Department

20.09.2022 - JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS ANTI-PLAGUE MABSEVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICESHAMBURG, GERMANT / ACCESSWIRE / September 20, 2022 / Evotec SE ... Seite 1